1) Basic product information

Always follow the advice given for your personal situation. Your healthcare professional may adjust your dose and monitoring schedule.

2) How Olumiant works (mechanism of action)

Olumiant (baricitinib) belongs to a group of medicines called JAK inhibitors. Your body’s immune signals include chemical messengers (cytokines) that can drive inflammation. These signals use pathways involving enzymes called Janus kinases (JAKs).

By blocking selected JAK pathways, baricitinib can help to reduce inflammatory activity, which may improve symptoms such as pain, stiffness, swelling, itching, and flare frequency depending on the condition being treated.

• Inflammation reduction: helps calm overactive immune signalling.
• Symptom improvement: may reduce the signs and symptoms of inflammatory disease.
• Longer-term effect: ongoing control depends on continued treatment and monitoring.

3) Pharmacokinetics (how the body handles the medicine)

Understanding pharmacokinetics can help explain why timing matters. In general terms, baricitinib is absorbed after oral dosing, then distributed throughout the body. It is cleared mainly via the kidneys, so kidney function influences how quickly the medicine is removed.

• Absorption: baricitinib is absorbed after you swallow the tablet.
• Peak effect time: it reaches highest blood levels within a few hours after taking a dose.
• Elimination: a large proportion is cleared through the kidneys.
• Half-life: the medicine remains in the body long enough to allow once daily dosing in many regimens.

If you have reduced kidney function, your clinician may choose a different dose or schedule, and may increase monitoring. Tell your healthcare professional about any history of kidney disease.

4) Typical use and timing

Olumiant is generally taken once daily as a long-term treatment for inflammatory disease. Your exact dose depends on your diagnosis, age, kidney function, and blood test results.

When to take it

• Try to take your tablet at the same time each day to keep levels steady.
• You can usually take it with or without food (see food interactions below).
• If you miss a dose, follow your local guidance or the instructions provided with your medicine. In general, do not take a double dose to make up for a missed tablet.

How quickly it may start to help

People may notice improvements at different speeds. Some inflammatory symptoms can improve within the first few weeks, while longer-term benefits may take several months, depending on the condition being treated.

5) Indications (what conditions it may be used for)

In the UK, baricitinib may be used for specific inflammatory conditions based on clinical assessment and eligibility. Indications can vary over time depending on regulatory updates and local prescribing criteria.

• Rheumatoid arthritis (RA): used in adults in accordance with current clinical guidance.
• Atopic dermatitis (eczema): in appropriate adults and some adolescents where criteria are met.
• Other inflammatory conditions: use may depend on updated UK guidance, specialist assessment, and eligibility.

If you are unsure whether Olumiant is suitable for you, check the label instructions and talk to your healthcare professional.

6) Dosing: what to expect

Dose regimens can differ by condition and patient factors. In the UK, baricitinib dosing is guided by the licensed product information and by specialist practice, including safety monitoring.

General dosing principles

• Renal function matters: kidney impairment can require a lower dose or different plan.
• Blood test results matter: your clinician will often check blood counts and other parameters.
• Response matters: if symptoms improve, clinicians may consider continued therapy; if side effects occur, adjustments may be needed.
• Infections: active or serious infections may require pausing treatment until resolved.

Common adult dosing patterns (illustrative)

The following gives a general idea of how clinicians think about dosing. Your exact prescription information should be used for your personal dose.

Do not change your dose unless your prescriber tells you to. If you experience side effects, contact your healthcare team.

7) Food interactions

Baricitinib can generally be taken with or without food. Food is not expected to have a major impact on whether the medicine can be taken safely.

• If taking with food helps you remember, that is fine.
• Keep a consistent routine day to day.
• If you have stomach upset, taking with food may be more comfortable for some people.

If you have dietary restrictions or digestive problems, speak with a pharmacist or your healthcare professional for personal advice.

8) Alcohol and medicine interactions

Olumiant is a prescription-only medicine and should be used under medical supervision. There is no specific “recommended” amount of alcohol that applies to everyone taking baricitinib, but general safety principles are important.

Alcohol

• Moderation is advisable, especially if you have liver-related issues or take other medicines that affect the liver.
• Alcohol may worsen overall health, sleep, and hydration, which can matter if you are unwell.
• If you feel more prone to infections or feel generally unwell, consider limiting alcohol while you recover.

Medicine interactions (important)

JAK inhibitors can interact with other medicines. The exact interaction depends on what you take. Tell your pharmacist or clinician about all medicines, including over-the-counter products, supplements, and vaccines.

• Other immunosuppressants: combining immune-suppressing medicines may increase infection risk.
• Strong inhibitors/inducers of enzymes: certain medicines can affect baricitinib levels in the body.
• Biologic therapies: the combination of biologics and JAK inhibitors may be restricted depending on condition and safety review.
• Common examples to check with a pharmacist: some antifungals, antivirals, antibiotics, anticonvulsants, and other targeted therapies.

Because interaction patterns are individualized, your pharmacy can help you review your current medicine list.

9) Safety profile: key things to know

Like all medicines, Olumiant can cause side effects. Most people tolerate baricitinib, but it has an important safety profile that requires clinical monitoring.

Important warnings (general)

• Infections: Olumiant may increase susceptibility to infections. Seek medical advice if you develop symptoms such as fever, persistent cough, burning when passing urine, unusual fatigue, or skin infections.
• Serious infections: if you feel suddenly very unwell or symptoms rapidly worsen, get urgent medical help.
• Blood counts: treatment may affect certain blood cell levels (for example, white blood cells and anaemia markers). Monitoring blood tests are commonly used.
• Cholesterol changes: some people see increased lipid levels; follow-up blood tests may be advised.
• Kidney function: because the medicine is cleared by the kidneys, kidney health is important for safe use.
• Thrombosis/clot risk: as with certain other therapies in this class, there may be an increased risk of blood clots in some circumstances; risk assessment is important.

Seek urgent help if you experience

• Signs of a severe allergic reaction: swelling of face/lips, difficulty breathing, widespread rash.
• Symptoms suggesting a blood clot: sudden shortness of breath, chest pain, coughing blood, one-sided leg swelling/pain.
• High fever or symptoms of serious infection that do not improve quickly.
• Severe abdominal pain, persistent vomiting, or unusual weakness (get medical advice promptly).

Common side effects (examples)

Side effects vary between individuals. Report bothersome or persistent symptoms to your healthcare professional.

• Headache
• Upper respiratory tract symptoms
• Nausea or stomach discomfort
• Changes seen in blood tests (anaemia, raised lipids)

Monitoring and follow-up

Many clinicians arrange periodic blood tests. Monitoring may include blood counts and other parameters, especially early in treatment. If you are asked to attend for tests, please do so promptly.

10) Practical use tips

• Use a daily routine: link your tablet to a consistent activity (e.g., breakfast) to improve adherence.
• Keep track of missed doses: use a phone reminder or pill organiser.
• Bring your medicine list: when visiting clinics, include all medicines, supplements, and recent changes.
• Don’t start new medicines without checking: particularly antibiotics, antivirals, antifungals, and other immune-modifying therapies.
• Infection precautions: good hand hygiene and avoiding close contact with people who have contagious infections can help.
• Vaccines: discuss vaccination plans with your healthcare team. Some vaccines may not be suitable during immune-modifying treatment.
• Hydration and general health: maintaining sleep, nutrition, and hydration supports recovery if you become unwell.

11) Alternative options (if appropriate)

Treatment choices depend on diagnosis, severity, prior therapies, comorbidities, and eligibility. If Olumiant is not suitable or not effective, clinicians may consider other approaches.

Possible alternatives

• Other DMARDs (disease-modifying antirheumatic drugs): conventional options such as methotrexate and others, where appropriate.
• Biologic therapies: targeted injections/infusions for inflammatory conditions.
• Other JAK inhibitors: alternative medicines within the same class (choice depends on safety profile and indication).
• Targeted therapies and supportive care: symptom relief and treatment of flares alongside disease control.

Your healthcare professional can discuss the pros and cons of different options for your individual case.

12) UK market and legal context (overview)

In the United Kingdom, medicines such as Olumiant are authorised for use by the relevant regulatory authorities and are supplied under specific legal frameworks. Baricitinib is provided for appropriate patient groups and is typically managed through clinical services and medicines governance pathways. Availability, prescribing criteria, and monitoring requirements may vary by condition and NHS/local formulary decisions.

If you are buying medicine online, it is important to use legitimate services and ensure products are sourced lawfully and supplied in accordance with applicable UK regulations.

13) Recent guidance and evolving recommendations

Guidance for JAK inhibitors is updated periodically as new safety data and clinical experience become available. Recommendations may change around:

• Patient selection (who is eligible)
• Dose adjustment criteria
• Monitoring schedules
• Risk mitigation steps (especially related to infections and clot risk)
• Management during acute illness

Your healthcare team will apply the most up-to-date UK advice. If you have questions about whether you are meeting the criteria for safe use, discuss this with your clinician or pharmacist.

14) Delivery and availability (UK online pharmacy information)

Online pharmacies in the UK typically provide ordering, payment, and home delivery options where permitted by law. Availability may vary depending on stock levels and tablet strength. Dispatch times and delivery windows can depend on your location, carrier service, and whether the product is in stock.

• In-stock items: may dispatch quickly once payment is confirmed.
• Out-of-stock items: may require ordering/stock replenishment; delivery may be delayed.
• Cold-chain: Olumiant tablets do not usually require refrigerated delivery, but always store according to label instructions.
• Packaging: check the outer packaging for integrity on arrival.

If you need help confirming stock and estimated delivery times, contact customer support.

15) Storing Olumiant

• Store at room temperature as directed on the packaging.
• Keep tablets in their original package to protect from moisture.
• Keep out of the sight and reach of children.
• Do not use after the expiry date on the pack.

16) FAQ

Is Olumiant only for rheumatoid arthritis?

No. While rheumatoid arthritis is a major indication, baricitinib may be used for other inflammatory conditions depending on regulatory approvals, clinical criteria, and specialist assessment.

How long does it take for Olumiant to work?

Some people notice improvement within weeks, but complete benefit may take longer. Your clinician may review your response over time and adjust the plan if needed.

Can I take Olumiant with food?

Yes. Olumiant can generally be taken with or without food. If food helps you tolerate it better, that is fine.

What should I do if I miss a dose?

Follow the instructions provided with your medicine or by your healthcare professional. In many cases, you should take it as soon as you remember unless it is close to the next scheduled dose. Do not take a double dose to make up for a missed tablet.

What infections should make me contact a clinician urgently?

Contact your healthcare team promptly if you develop fever, severe fatigue, worsening cough or shortness of breath, painful urination, a skin infection, or any infection that becomes serious quickly.

Can I drink alcohol while taking Olumiant?

Moderate alcohol intake may be acceptable for some people, but it depends on your overall health and other medicines. If you have liver issues or feel unwell, consider avoiding alcohol and seek medical advice.

Are vaccinations safe on Olumiant?

Some vaccines may not be recommended during immune-modifying treatment. Discuss your vaccination plan with your healthcare team to ensure timing is safe.

Does Olumiant interact with other medicines?

Yes, interactions can occur, especially with other immune-modifying treatments or medicines that affect drug metabolism. Always provide your full medicine list (including supplements and over-the-counter products) to your pharmacist or clinician.

Who should be particularly cautious when taking baricitinib?

People with a history of recurrent infections, reduced kidney function, older age, or those with additional risk factors for blood clots may require extra caution and closer monitoring.

What monitoring will I need?

Monitoring often includes periodic blood tests to check blood cell levels and other parameters, particularly early in treatment and after dose changes.